

4 March 2026

## COMPLETION OF ON-MARKET SHARE BUY-BACK

Mach7 Technologies Limited's ("M7T's" or the "Company's") on-market share buy-back announced on 30 January 2025 ("On-Market Buy-Back") ended on 3 March 2026.

The Company previously announced that it would purchase up to \$5M of fully paid ordinary shares ("Shares") as part of the On-Market Buy-back program. In total 6,273,000 shares were purchased for \$2,236,019.43 at an average price of \$0.3501.

Further details in relation to the completion of the On-Market Buy-back are set out in the final buy-back notification lodged today with ASX.

This release was authorised by the Board of Mach7 Technologies Limited

For more information, contact:

**Investor Relations:**

Francoise Dixon  
+61 (0) 412 292 977  
[ir@mach7t.com](mailto:ir@mach7t.com)

**About Mach7 Technologies:**

Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, delivering advanced data management and diagnostic viewing solutions to healthcare organisations worldwide. The Mach7 Enterprise Imaging Solution (EIS) is a next-generation solution combining a powerful Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and robust diagnostic workflow applications. Built for maximum flexibility and scalability, Mach7 empowers customers to implement a complete enterprise imaging ecosystem or deploy modular components that fit their unique needs. Today, Mach7 supports a diverse global network, from large integrated delivery networks (IDNs) and national health systems to independent provider groups and private radiology practices. Visit [Mach7t.com](http://Mach7t.com) for more information.